AGB101 / Agni Bio - LARVOL DELTA

AGB101 PDP: Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: Johns Hopkins University | Trial completion date: Sep 2026 ➔ Dec 2026 | Trial primary completion date: Sep 2026 ➔ Dec 2026

Trial completion date • Trial primary completion date • CNS Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

AGB101-CN: Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults (clinicaltrials.gov) - P2 | N=60 | Active, not recruiting | Sponsor: Johns Hopkins University | Recruiting ➔ Active, not recruiting

Enrollment closed • Alzheimer's Disease • CNS Disorders • Dementia • APOE

AGB101, a first-in-class Vβ17 x DLL3 bispecific antibody, selectively redirects Vβ17 T memory cells to drive robust DLL3 dependent anti-tumor activity (AACR 2026) - "In contrast, treatment with the CD3 x DLL3 bsAb, tarlatamab, leads to a rapid expansion of the entire T cell population including non-cytolytic subsets. Lastly, AGB101 demonstrated robust anti-tumor activity in vivo in two DLL3 expressing SCLC tumor models. Collectively, our data demonstrate that TCR-directed targeting improves the quality, magnitude, and durability of anti-tumor T cell responses and these features of AGB101 mediated anti-tumor activity highlight selective Vβ17 T cell redirection as a promising next-generation immunotherapeutic approach to enable more efficient immune system engagement, with the potential to provide improved clinical benefit to patients."

Bispecific • Late-breaking abstract • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor • CCR7 • CD8 • DLL3 • IL1B • IL6 • TNFA